Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories

Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.

• Source: Shutterstock

Austrian biotech Marinomed is taking its red seaweed-based Carragelose platform into new OTC categories as it steps up efforts to achieve operating profitability.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Clasado Divests Bimuno Prebiotic Consumer Brand To UK’s Eleat

 
• By 

Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.

US Consumer Health Market People News: Kemin Loses Founder, BASF Corp. CEO, Bucked Up Rep

 

Kemin Industries founder, human and animal health care innovator RW Nelson dies; Heather Remley moves from BASF’s Global Engineering to North America business helm; and golfer Bryson DeChambeau links up with Bucked Up.

Givaudan Has UTI Health Claim Turned Down In EU

 
• By 

European Food Safety Authority finds no cause and effect relationship between Givaudan's Pacran supplement and defense against urinary tract infections.